01—Abstract
Summary
Summary of the 10-K filed February 24, 2016. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson's 2016 10-K filing reveals a year of transition, with total sales decreasing by 5.7% to $70.1 billiona, primarily due to unfavorable currency impacts (7.5%) and the introduction of competitive products in the Hepatitis C market.
The company continues to invest heavily in research and development, allocating $9.0 billionb (12.9% of sales) to innovation across its three segments: Consumer, Pharmaceutical, and Medical Devices. The Pharmaceutical segment experienced operational growth, largely driven by strong performance in Immunology and Oncology, though impacted by Hepatitis C product competition. The Medical Devices segment saw a decline in sales, partly due to divestitures of the Cordis and Ortho-Clinical Diagnostics businesses, but showed operational resilience in key areas like Orthopaedics and Surgery.
The company also announced a significant restructuring initiative within its Medical Devices segment, aiming for annualized pre-tax cost savings of $800 million to $1.0 billionc. Financially, the company generated robust operating cash flow of $19.3 billion.
Despite a decrease in earnings before taxes due to factors like currency headwinds and restructuring charges, Johnson & Johnson demonstrated a strong commitment to shareholders by increasing its dividend for the 53rd consecutive year and continuing its share repurchase program. The company's financial position remains strong, with significant cash reserves and a manageable debt-to-capital ratio, positioning it to navigate market challenges and invest in future growth.
02—Key points
Key Highlights
- Total sales decreased by 5.7% to $70.1 billion in 2015, influenced by a significant negative currency impact of 7.5% and competition in the Hepatitis C drug market.
- Research and Development (R&D) spending increased to $9.0 billion (12.9% of sales), highlighting the company's commitment to innovation across its key segments.
- The Pharmaceutical segment showed operational growth, with key drivers including STELARA®, SIMPONI®/SIMPONI ARIA®, and strong performance in Oncology (IMBRUVICA®, ZYTIGA®), though REMICADE® sales declined due to biosimilar competition outside the US.
- The Medical Devices segment experienced an 8.7% sales decrease, partly due to divestitures of Cordis and Ortho-Clinical Diagnostics, but showed operational growth in areas like Advanced Surgery and Orthopaedics (ATTUNE® Knee System).
- Johnson & Johnson announced a significant restructuring in the Medical Devices segment, expecting $800 million to $1.0 billion in annualized pre-tax cost savings.
- Operating cash flow remained strong at $19.3 billion, supporting dividends and share repurchases.
- The company increased its dividend for the 53rd consecutive year, demonstrating a consistent return of capital to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 24, 2016Financial Statements
| Revenue | $70.07B |
| Cost of Revenue | $21.54B |
| Gross Profit | $48.54B |
| SG&A Expenses | $21.20B |
| Interest Expense | $552.00M |
| Net Income | $15.41B |
| EPS (Basic) | $5.56 |
| EPS (Diluted) | $5.48 |
| Shares Outstanding (Basic) | 2.77B |
| Shares Outstanding (Diluted) | 2.81B |
05—Questions
Frequently Asked Questions
What was the primary driver for the decrease in total sales in 2015?
The primary driver for the decrease in total sales in 2015 was a combination of unfavorable currency impacts, which accounted for a 7.5% decrease, and the introduction of competitive products in the Hepatitis C market, which negatively impacted sales by 2.7%.
How is Johnson & Johnson addressing challenges in the Medical Devices segment?
Johnson & Johnson is implementing a significant restructuring program within its Medical Devices segment, which is expected to generate $800 million to $1.0 billion in annualized pre-tax cost savings. This initiative aims to improve go-to-market strategies, accelerate innovation, and streamline operations.
What is the outlook for the Pharmaceutical segment, particularly concerning REMICADE®?
The Pharmaceutical segment demonstrated operational growth, driven by products like STELARA® and SIMPONI®. However, REMICADE® sales experienced a decline outside the U.S. due to the introduction of biosimilar versions. The company is actively defending its patents related to REMICADE® and anticipates potential further reductions in sales in markets where biosimilars are present.
How did the company manage its cash flow and return capital to shareholders?
Johnson & Johnson generated strong operating cash flow of $19.3 billion in 2015. This robust cash generation allowed the company to fund its ongoing operations, invest in R&D, and return capital to shareholders through dividends, which were increased for the 53rd consecutive year, and share repurchases under its authorized program.
06—Continue